Polymersomal Poly(I:C) Self‐Magnifies Antitumor Immunity by Inducing Immunogenic Cell Death and Systemic Immune Activation
Jingyi Wang,Beibei Guo,Zhiwei Sun,Songsong Zhao,Li Cao,Zhiyuan Zhong,Fenghua Meng
DOI: https://doi.org/10.1002/adhm.202400784
IF: 10
2024-06-21
Advanced Healthcare Materials
Abstract:Immunotherapy has emerged as a powerful weapon against lung cancer, yet only a fraction of patients respond positively to the treatment. Poly(I:C) effectively triggers both innate and adaptive immunity. It is also capable of inducing immunogenic cell death (ICD) in tumor cells. However, its efficacy is hindered by its instability in vivo and limited cellular uptake. To address this, we encapsulated poly(I:C) in cRGD‐targeted polymersomes (t‐PPIC), which significantly increased its stability and uptake, resulting in the vital activation of dendritic cells (DCs) and apoptosis of lung tumor cells in vitro. In a murine LLC lung tumor model, systemic administration of t‐PPIC effectively suppressed tumor growth and led to striking survival benefits, with 40% of the mice becoming tumor‐free. Notably, t‐PPIC provoked stronger apoptosis and ICD in tumor tissue and elicited a more potent stimulation of DCs, recruitment of NK cells, and activation of CD8+ T cells, compared to free poly(I:C) and nontargeted PPIC controls. Furthermore, when combined with immune checkpoint inhibitors or radiotherapy, t‐PPIC amplified the antitumor immune response, resulting in complete regression in 60% of the mice. These compelling findings underscore the potential of integrin‐targeted polymersomal poly(I:C) to enhance antitumor immunity by simultaneously inducing ICD and systemic immune activation. This article is protected by copyright. All rights reserved
nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials